HB 1426 creates a new chapter in the Indiana Code on “liability shield products,” defined as certain medical, pharmaceutical, biological, or technological products that have been designated immune from liability under federal law. The bill requires such products to undergo a placebo-controlled study before they may be distributed, manufactured, marketed, or administered in Indiana, and it requires that the study run for at least five years while continuously collecting specified safety outcome metrics. Those metrics include allergenicity, carcinogenicity, fertility impact, immunogenicity, mutagenicity, and reactogenicity.
The bill also directs the Indiana Department of Health to monitor and publish adverse-outcome information using state health data systems, issue alerts and bulletins about adverse consequences, and adopt a public policy for data collection by January 1, 2026. Manufacturers would have to submit documentation by July 1, 2028, showing that a placebo-controlled study has been initiated, and later submit compliance reports by December 31, 2030, confirming completion of the study and reporting final results. The bill further states that individuals have a right to refuse a liability shield product and may not be coerced or threatened into using one.
HB 1426 would also create enforcement mechanisms. The attorney general could seek injunctive relief, civil penalties, and attorney’s fees for violations of the documentation, compliance, refusal-right, or study requirements, and the bill also authorizes private lawsuits by injured individuals for injunctive relief, compensatory damages, and fees. The bill declares an emergency, indicating it would take effect upon passage.
Its legal impact would be significant because it would impose state-level testing, reporting, and enforcement requirements on products that are already protected from liability under federal law, potentially affecting manufacturers, distributors, health care providers, and state agencies involved in public health monitoring. It would add new definitions to Indiana’s health code and create a new regulatory chapter focused on pre-market and post-market safety surveillance for these products.
There is no recorded committee testimony or vote history in the provided materials, so the overall sentiment cannot be measured from debate or roll-call data. Based on the bill text alone, the measure appears strongly precautionary and regulatory, emphasizing product safety, transparency, and individual refusal rights. Likely points of contention would include the feasibility and cost of a five-year placebo-controlled study, the scope of products covered, the interaction with federal immunity or preemption, and the bill’s private right of action and civil penalties.
HB 1426 would amend Indiana health law by adding definitions and creating a new chapter governing “liability shield products.” It would require manufacturers to conduct long-term placebo-controlled studies, report initiation and completion of those studies to the Indiana Department of Health, and make results publicly available. The bill also expands state monitoring authority over adverse outcomes and creates enforcement tools for the attorney general and private plaintiffs, potentially affecting manufacturers, distributors, health care providers, and patients in Indiana.
No committee transcripts or votes were provided, so there is no documented legislative sentiment from debate or roll-call history. From the bill text, the measure is framed as a public-safety and transparency bill, with a strong regulatory posture toward products covered by federal liability immunity. The overall tone is precautionary and consumer-protective, but the absence of discussion records means support or opposition cannot be directly assessed.
The main likely points of contention are the bill’s requirement that federally immune products undergo a five-year placebo-controlled study before use in Indiana, the administrative burden on manufacturers, and the potential conflict with federal law or existing federal immunity frameworks. Another likely issue is the bill’s broad enforcement scheme, which allows both the attorney general and private individuals to sue, seek damages, and recover fees. The refusal-right provision and coercion ban could also raise questions about implementation in health care settings and public health programs.